Interview with Dan Brown , Managing Director, Genzyme Australia
What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of…
Address: Level 3 21 Solent Circuit BAULKHAM HILLS NSW 2153 AUSTRALIA
,Australia
Tel: 1800 224 321
Web: http://www.novonordisk.com.au/documents/home_page/document/index.asp
At Novo Nordisk, we strive to be the world’s leading diabetes care company, and each of us takes this vision personally. Our highest priority is the health and well being of people living with diabetes. We respect their many lifestyles and individual needs and develop our therapies with those differences in mind.
Through intensive research, Novo Nordisk has created innovative insulin delivery systems as well as disposable needles that were designed to help reduce pain and fear of injection. Using recombinant technology, we have developed novel insulin and insulin analog formulations. We also offer patient education programs, continuing medical education for healthcare professionals, and more, as we strive to meet the individual needs of our customers!
In addition, we hold a leading position in other therapeutic areas, such as coagulation disorders, growth hormone disorders, and hormone therapy for women.
Novo Nordisk has affiliate offices in 81 countries and approximately 27,000 full-time employees worldwide. We reach out to 179 countries around the world with our products and programs. We operate manufacturing facilities in six countries, including the United States.
Novo Nordisk has a comprehensive range of products relating to diabetes, haemostasis, growth and the menopause.
What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the national industry association for innovative pharmaceutical companies. . Just about every company engaged in…
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
New Government health priorities and policies, highlighting those concerning preventive health. The Rudd Labor Government’s goal in health is to create a modern health system designed for the health needs…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Pharmacor is one of the newest entities on the Australian pharmaceutical market. Would you please introduce the company to let Pharmaceutical Executive readers understand more about the Pharmacor story? Pharmacare…
Would you please introduce the PBAC and the role it plays in Australia’s pharmaceutical sector? The Pharmaceutical Benefits Advisory Committee (PBAC) is a statutory committee of the Australian government which…
Molteni was created in 1892 and progressively developed a strong manufacturing base, a very active R&D department and a growing international presence. Could you introduce the story behind such achievements?…
To begin, would you please introduce Medicines Australia to Pharmaceutical Executive readers? Medicines Australia is the association that represents the country’s research-based pharmaceutical industry. With approximately 50 members, the organization…
Your distinguished career in health research leadership and management has seen you through a variety of prestigious positions, not to mention the Order of Australia. Most recently you were appointed…
Australia, the “land down under” to many Westerners, is sometimes left at just that — out of sight, and out of mind. But investors who ignore Australia do so…
See our Cookie Privacy Policy Here
